Atara biotherapeutics to present recent progress and key upcoming milestones at the 42nd annual j.p. morgan healthcare conference

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced pascal touchon, president and chief executive officer of atara, will present the company's 2023 accomplishments across strategic priorities and key upcoming milestones at the 42nd annual j.p. morgan healthc.
ATRA Ratings Summary
ATRA Quant Ranking